Skip to content

Sequential lysosome-microtubule targeted transformable nanosystem for long-lasting photodynamic-based multimodal therapy of breast cancer.

Sep 2026 · Journal of Controlled Release · pp. 115336 · 0 citations · 56 references
Medicine

TL;DR

A matrix metalloproteinase-2-responsive shape transformable nanosystem (CpA) that self-assembles from the amphiphilic conjugate Ce6-pep-iABS exhibits enhanced cellular uptake and induce sequential LMP and microtubule disruption, which synergizes with photodynamic therapy (PDT) to amplify immunogenic cell death, activate robust antitumor immunity, and establish long-lasting immunological memory.

Abstract

Subcellular organelle-targeted strategies hold great promise in cancer therapy. Peptide nanofibers can induce lysosomal membrane permeabilization (LMP) and microtubule disruption, yet their in vivo delivery remains challenging. Here, we report a matrix metalloproteinase-2 (MMP-2)-responsive shape transformable nanosystem (CpA) that self-assembles from the amphiphilic conjugate Ce6-pep-iABS, comprising the photosensitizer chlorin e6 (Ce6) and the carbonic anhydrase IX (CA IX) inhibitor 4-(2-aminoethyl) benzenesulfonamide (ABS) linked via an MMP-2-cleavable peptide. Upon reaching tumors, CpA transforms from spherical nanoparticles into nanofibers, enabling deep penetration and long-term retention in tumor. The released ABS segments continuously inhibit CA IX to reverse extracellular acidosis and alleviate immunosuppression. Crucially, the transformed nanofibers exhibit enhanced cellular uptake and induce sequential LMP and microtubule disruption, which synergizes with photodynamic therapy (PDT) to amplify immunogenic cell death (ICD), activate robust antitumor immunity, and establish long-lasting immunological memory. This synergistic effect significantly inhibits tumor growth and prevents tumor recurrence and metastasis, presenting an innovative paradigm for multimodal cancer therapy by integrating sequential organelle targeting, tumor microenvironment modulation, and intensified PDT.

View source

Similar papers

Sep 2026

CD44 Receptor-Guided Hyaluronic Acid Nanogels with Dual-Stimuli Responsiveness and Lysosomal Disruption Capability for In Vivo Protein Delivery in Lung Cancer Treatment.

Protein delivery nanosystems must balance stable loading, barrier navigation, and targeted, controlled release. Herein, a pH/ROS dual-responsive nanogel (PRNG) was constructed by forming dynamic boronic ester crosslinkers between PEGylated hyaluronic acid bearing diethylenetriamine-grafted-catechol groups (PEG-HA-Dien-...

Wei Jiang, Wei Sun, Si-Qi Zhan et al. · 0 citations
Open access Sep 2026

Rational Design of Porphyrin-Based Nano-Prodrug for Overcoming ROS Resistance and Synergistic Photodynamic Cancer Therapy.

Porphyrin-based photosensitizers (PSs) are among the most widely explored agents for photodynamic therapy (PDT), yet their clinical translation is severely limited by poor biocompatibility, aggregation-induced quenching, insufficient tumor selectivity, and the intrinsic reactive oxygen species (ROS) resistance of cance...

Yi-Hui Ai, Chong-Zhi Wu, Zhi-Yao Li et al. · 0 citations
Oct 2026

A Novel Viscosity-Responsive Fluorescent Photosensitizer with Imidazole-Coumarin Conjugation Induces Lysosome-Mediated Ferroptosis in Cancer Cells.

Lysosomes play a crucial role in ferroptosis, presenting a dual opportunity for disease diagnosis and targeted cancer therapy. However, existing lysosomal probes generally lack the photosensitizing capabilities necessary to induce ferroptosis. Herein, we report the development of a novel series of benzimidazole-coumari...

Gan Li, Zhuo-Liang Zhou, Ming-Hao Hu · 0 citations
Open access Sep 2026

A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

By integrating multi-organelle targeting with molecular therapy, diNP@PDs offer an innovative strategy for both imaging and inhibiting tumor metastasis, highlighting the potential of interorganelle approaches in oncology.

Ru-Jing Wang, Lang Zou, Dan-Dan Mi et al. · 0 citations
Oct 2026

A nucleus-targeting type-I photosensitive nanoplatform for DNA-binding-enhanced photodynamic therapy.

In vitro and in vivo studies confirmed the effective ROS generation, antitumor efficacy, and good biocompatibility of the nanoplatform, and the DNA-binding-enhanced PDT strategy provides a promising pathway for precision phototherapeutics.

Zhi-Qiang Zhang, Wen-Cheng Wang, Zhe Guo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.